Use of reagents for detecting RNF111 S255 phosphorylation in the preparation of products for the diagnosis of colorectal cancer
By detecting antibodies at the phosphorylation site of RNF111 S255, the problem of lacking quantifiable biomarkers has been solved, enabling precise diagnosis and prognostic assessment of colorectal cancer and providing important clinical guidance.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ACADEMY OF MILITARY MEDICAL SCIENCES
- Filing Date
- 2026-06-15
- Publication Date
- 2026-07-17
AI Technical Summary
Current technologies lack directly assessable and quantifiable biomarkers to evaluate chromosomal instability (CIN) levels, making it difficult to effectively diagnose colorectal cancer and assess its prognosis.
Reagents for detecting RNF111 S255 phosphorylation, including antibodies that specifically bind to phosphorylated RNF111 S255 proteins, are used to prepare products for diagnosing colorectal cancer, assessing prognosis, and predicting precancerous lesions.
The RNF111 S255 phosphorylation site, as a biomarker, can specifically identify colorectal cancer, assess its prognosis, and predict precancerous lesions, providing precise clinical diagnosis and treatment guidance.
Smart Images

Figure CN122410033A_ABST